| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
169,410,000 |
| Market
Cap: |
97.83(M) |
| Last
Volume: |
3,856,623 |
Avg
Vol: |
3,845,860 |
| 52
Week Range: |
$0.35 - $0.885 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Inovio Pharmaceuticals is a biotechnology company focused on bringing the designed deoxyribonucleic acid (DNA) medicines and vaccines to help protect people from infectious diseases, including COVID-19, and to help treat people with cancer, and conditions associated with human papillomavirus. Co.'s DNA medicines pipeline is comprised of three types of product candidates: prophylactic DNA vaccines, therapeutic DNA immunotherapies, and DNA encoded monoclonal and bispecific antibodies, all of which utilize the two components of Co.'s integrated platform, SynCon® and CELLECTRA®. Co. is evaluating the feasibility of, conducting or planning clinical studies of its DNA medicines.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
5,700 |
49,676 |
| Total Sell Value |
$0 |
$0 |
$3,192 |
$85,601 |
| Total People Sold |
0 |
0 |
1 |
3 |
| Total Sell Transactions |
0 |
0 |
1 |
7 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Shea Jacqueline Elizabeth |
Chief Operating Officer |
• – – |
2022-03-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,666 |
83,802 |
|
- |
|
| Miller Ann Calby |
Director |
– • – |
2022-03-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,273 |
29,534 |
|
- |
|
| Benito Simon X |
Director |
– • – |
2022-03-16 |
4 |
AS |
$3.16 |
$6,320 |
D/D |
(2,000) |
57,305 |
|
-38% |
|
| Benito Simon X |
Director |
– • – |
2022-03-16 |
4 |
OE |
$2.20 |
$4,400 |
D/D |
2,000 |
59,305 |
|
- |
|
| Weiner David B. |
Director |
– • – |
2022-03-14 |
4 |
AS |
$3.20 |
$13,066 |
D/D |
(4,083) |
883,625 |
|
-37% |
|
| Humeau Laurent |
Chief Scientific Officer |
• – – |
2022-03-11 |
4 |
D |
$3.22 |
$66,519 |
D/D |
(20,658) |
134,684 |
|
- |
|
| Humeau Laurent |
Chief Scientific Officer |
• – – |
2022-03-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
59,737 |
155,342 |
|
- |
|
| Kies Peter |
CFO |
• – – |
2022-03-11 |
4 |
D |
$3.22 |
$101,140 |
D/D |
(31,410) |
179,284 |
|
- |
|
| Kies Peter |
CFO |
• – – |
2022-03-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
59,737 |
210,694 |
|
- |
|
| Weiner David B. |
Director |
– • – |
2022-03-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,667 |
887,708 |
|
- |
|
| Shea Jacqueline Elizabeth |
Chief Operating Officer |
• – – |
2022-03-11 |
4 |
D |
$3.22 |
$83,636 |
D/D |
(25,974) |
67,136 |
|
- |
|
| Shea Jacqueline Elizabeth |
Chief Operating Officer |
• – – |
2022-03-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
59,737 |
93,110 |
|
- |
|
| Kim Jong Joseph |
Chief Executive Officer |
• • – |
2022-03-11 |
4 |
D |
$3.22 |
$127,828 |
D/D |
(39,698) |
1,422,627 |
|
- |
|
| Kim Jong Joseph |
Chief Executive Officer |
• • – |
2022-03-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
139,387 |
1,462,325 |
|
- |
|
| Weiner David B. |
Director |
– • – |
2022-03-09 |
4 |
AS |
$3.33 |
$13,596 |
D/D |
(4,083) |
876,041 |
|
-41% |
|
| Kies Peter |
CFO |
• – – |
2022-03-08 |
4 |
D |
$3.26 |
$36,796 |
D/D |
(11,287) |
150,957 |
|
- |
|
| Kies Peter |
CFO |
• – – |
2022-03-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,466 |
162,244 |
|
- |
|
| Kim Jong Joseph |
Chief Executive Officer |
• • – |
2022-03-08 |
4 |
D |
$3.26 |
$59,143 |
D/D |
(18,142) |
1,322,938 |
|
- |
|
| Kim Jong Joseph |
Chief Executive Officer |
• • – |
2022-03-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
63,700 |
1,341,080 |
|
- |
|
| Humeau Laurent |
Chief Scientific Officer |
• – – |
2022-03-08 |
4 |
D |
$3.26 |
$22,435 |
D/D |
(6,882) |
95,605 |
|
- |
|
| Humeau Laurent |
Chief Scientific Officer |
• – – |
2022-03-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
19,900 |
102,487 |
|
- |
|
| Weiner David B. |
Director |
– • – |
2022-03-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,666 |
880,124 |
|
- |
|
| Kies Peter |
CFO |
• – – |
2022-02-26 |
4 |
D |
$3.22 |
$40,427 |
D/D |
(12,555) |
140,778 |
|
- |
|
| Kies Peter |
CFO |
• – – |
2022-02-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
22,545 |
153,333 |
|
- |
|
| Humeau Laurent |
Chief Scientific Officer |
• – – |
2022-02-26 |
4 |
D |
$3.22 |
$27,515 |
D/D |
(8,545) |
82,587 |
|
- |
|
488 Records found
|
|
Page 3 of 20 |
|
|
